The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD K.K; Ono Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; MSD K.K; Novartis; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst)
Association of gut microbiome with immune status and clinical response in solid tumor patients who received on anti-PD-1 therapies.
 
Shota Fukuoka
No Relationships to Disclose
 
Motooka Daisuke
No Relationships to Disclose
 
Yosuke Togashi
No Relationships to Disclose
 
Eri Sugiyama
No Relationships to Disclose
 
Hibiki Udagawa
Honoraria - Amco; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Abbvie; MSD
 
Keisuke Kirita
No Relationships to Disclose
 
Takahiro Kamada
No Relationships to Disclose
 
Akihito Kawazoe
Research Funding - Dainippon Sumitomo Pharma (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Koichi Goto
Honoraria - AbbVie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Life Technologies; Lilly; Merck Serono; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; RIKEN GENESIS; Roche; SRL Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Otsuka
Research Funding - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Ignyta; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
 
Toshihiko Doi
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Sumitomo Dainippon; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Shota Nakamura
No Relationships to Disclose
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Ono Pharmaceutical (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Zenyaku Kogyo (Inst)